Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

BACKGROUND Kirsten ras (Ki-ras) gene mutations occur early in the progression of colorectal adenoma to carcinoma. The aim of this collaborative study was to clarify the association between Ki-ras mutations, patient outcome, and tumor characteristics by use of data from colorectal cancer patients worldwide. METHODS Investigators who had published data on Ki-ras and colorectal cancer were invited to complete a questionnaire for each patient entered into a database. Two-sided statistical tests were used to analyze data. RESULTS Patients (n = 2721) were recruited from 22 groups in 13 countries. Mutations of Ki-ras codon 12 (wild type = GGT = glycine) or codon 13 (wild type = GGC = glycine) were detected in 37.7% of the tumors; 80.8% (584 of 723) of all the specified mutations occurred in codon 12, and 78.1% (565 of 723) of all the specified mutations were at the second base of either codon. Mutations were not associated with sex, age, tumor site, or Dukes' stage. Mutation rates seen in patients with sporadic tumors were comparable to those observed in patients with a predisposing cause for their cancer. Poorly differentiated tumors were less frequently mutated (P = .002). Multivariate analysis suggested that the presence of a mutation increased risk of recurrence (P<.001) and death (P = .004). In particular, any mutation of guanine (G) to thymine (T) but not to adenine (A) or to cytosine (C) increased the risk of recurrence (P = .006) and death (P<.001). When individual, specific mutations were evaluated, only valine codon 12 was found to convey an independent, increased risk of recurrence (P = .007) and death (P = .004). CONCLUSIONS Ki-ras mutations are associated with increased risk of relapse and death, but some mutations are more aggressive than others.

[1]  A. Norman,et al.  K-ras mutations in patients with early colorectal cancers , 1997, Gut.

[2]  C. Kittas,et al.  K-ras mutation in Greek patients with poorly and moderately differenciated tumours of the lower intestinal tract. , 1997, Anticancer research.

[3]  G. Gaudernack,et al.  K-ras mutations and prognosis in large-bowel carcinomas. , 1997, Scandinavian journal of gastroenterology.

[4]  J. C. Lee,et al.  K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. , 1996, Anticancer research.

[5]  T. Iwama,et al.  Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. , 1996, Gastroenterology.

[6]  W. Giaretti,et al.  Intratumor heterogeneity of K-ras2 mutations in colorectal adenocarcinomas: association with degree of DNA aneuploidy. , 1996, The American journal of pathology.

[7]  K. Isono,et al.  Detection of DCC and Ki‐ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence , 1996, Cancer.

[8]  D. Smith,et al.  C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. , 1996, European journal of cancer.

[9]  K. Bland,et al.  Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. , 1995, American journal of surgery.

[10]  E. Kay,et al.  ras and p53 in the prediction of survival in Dukes' stage B colorectal carcinoma , 1995, Clinical molecular pathology.

[11]  Mackay,et al.  Mutant K-ras oncogenes in colon cancers Do not predict Patient's chemotherapy response or survival , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  E. Cho,et al.  Point mutations in the c‐K‐ras 2 gene in multiple colorectal carcinomas , 1995, Journal of gastroenterology and hepatology.

[13]  M. Maggard,et al.  K-ras status does not predict successful hepatic resection of colorectal cancer metastasis. , 1995, Archives of surgery.

[14]  B. Iacopetta,et al.  The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short‐term prognostic indicators of survival , 1994, International journal of cancer.

[15]  M. Morrin,et al.  Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. , 1994, Gut.

[16]  K. Omura,et al.  Prognostic factors of colorectal cancer: K‐ras mutation, overexpression of the p53 protein, and cell proliferative activity , 1994, Journal of surgical oncology.

[17]  J. Arends,et al.  Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. , 1994, Cancer research.

[18]  T. Sugimura,et al.  Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas. , 1994, Cancer research.

[19]  J. Benhattar,et al.  K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. , 1994, The American journal of pathology.

[20]  G. Gaudernack,et al.  K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. , 1994, British Journal of Cancer.

[21]  S. Finkelstein,et al.  Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K‐ras‐2 mutation type , 1993, Cancer.

[22]  S. Knežević-Ušaj,et al.  Prevalence of G‐TO‐T transversions among K‐ras oncogene mutations in human colorectal tumors in Yugoslavia , 1993, International journal of cancer.

[23]  J. Benhattar,et al.  Prognostic significance of K-ras mutations in colorectal carcinoma. , 1993, Gastroenterology.

[24]  G. Taylor,et al.  Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. , 1993, Gastroenterology.

[25]  D. Huhn,et al.  Position specificity of Ki-ras oncogene mutations during the progression of colorectal carcinoma. , 1993, Oncology.

[26]  H. Rabes,et al.  K‐ras point mutations in human colorectal carcinomas: Relation to aneuploidy and metastasis , 1992, International journal of cancer.

[27]  O. Delattre,et al.  Survival and acquired genetic alterations in colorectal cancer. , 1992, Gastroenterology.

[28]  J. Rose,et al.  Lack of ras mutations and prediction of long-term survival in carcinoma of the colon. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[29]  S. Rodenhuis,et al.  Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver , 1991, International journal of cancer.

[30]  G. Taylor,et al.  c-Ki-ras gene mutations in dysplasia and carcinomas complicating ulcerative colitis. , 1991, British Journal of Cancer.

[31]  H. Zhang,et al.  Ras p21 expression in relation to histopathological variables and prognosis in colorectal adenocarcinoma. , 1991, Acta oncologica.

[32]  P. Rabinovitch,et al.  c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. , 1990, Gastroenterology.

[33]  M. Leppert,et al.  Allelic Loss in Colorectal Carcinoma , 1989 .

[34]  Y. Nakamura,et al.  Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]. , 1989, JAMA.

[35]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[36]  Z. Cope.  The National Hospital , 1900, The Hospital.